Home Applications 022180 Application 022180
Type NDA
Sponsor AMAG PHARMS INC Application Products# Product, Drug, Ingredient table Product Drug Ingredient Form Strength Reference drug Reference standard 001 FERAHEME FERUMOXYTOL SOLUTION;INTRAVENOUS EQ 510MG IRON/17ML (EQ 30MG IRON/ML) Yes Yes
Source provenance: Browse the complete Orange Book source catalog · source snapshot 45 .
Orange Book products# Current product rows page 1 of 1 · 1 matching rows.
Application-product, Trade name, Ingredient table Application-product Trade name Ingredient Strength Dosage form / route TE codes RLD / RS Approval date N022180-001 FERAHEME FERUMOXYTOL EQ 510MG IRON/17ML (EQ 30MG IRON/ML) SOLUTION / INTRAVENOUS AB RLD, RS 2009-06-30
Therapeutic equivalence codes# Current TE-code rows page 1 of 1 · 1 matching rows.
Application-product, TE code table Application-product TE code N022180-001 AB
Observed Orange Book product history# Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
Product history page 2 of 2 · 45 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Trade name Strength Dosage form / route Product TE source text RLD / RS Approval date Source SHA-256 2022-11-12 20:34 UTC · 5 captures of this ZIP 2022-11 N022180-001 FERAHEME EQ 510MG IRON/17ML (EQ 30MG IRON/ML) SOLUTION / INTRAVENOUS AB RLD, RS 2009-06-30 3a93d1ddd44b…2022-10-28 04:53 UTC 2022-10 N022180-001 FERAHEME EQ 510MG IRON/17ML (EQ 30MG IRON/ML) SOLUTION / INTRAVENOUS AB RLD, RS 2009-06-30 f41ea6bd6efb…2022-09-29 23:25 UTC 2022-09 N022180-001 FERAHEME EQ 510MG IRON/17ML (EQ 30MG IRON/ML) SOLUTION / INTRAVENOUS AB RLD, RS 2009-06-30 e64feba35796…2022-07-09 03:26 UTC · 3 captures of this ZIP 2022-07 N022180-001 FERAHEME EQ 510MG IRON/17ML (EQ 30MG IRON/ML) SOLUTION / INTRAVENOUS AB RLD, RS 2009-06-30 cb3db0bc1861…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N022180-001 FERAHEME EQ 510MG IRON/17ML (EQ 30MG IRON/ML) SOLUTION / INTRAVENOUS AB RLD, RS 2009-06-30 a50c72e98297…
Observed Orange Book normalized TE history# Observed Orange Book patent history# Patent history page 1 of 2 · 54 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Patent Expiration Use code Coverage / status Submission date Source SHA-256 2022-06-29 02:47 UTC · 2 captures of this ZIP 2022-06 N022180-001 6599498 2023-06-30 Drug substance, Drug product 5c6f7cd8ea54…2022-04-08 23:34 UTC 2022-04 N022180-001 6599498 2023-06-30 Drug substance, Drug product 5d02ea3f76ae…2022-04-04 05:41 UTC 2022-04 N022180-001 6599498 2023-06-30 Drug substance, Drug product 4b0b4de00fa7…2019-12-13 00:20 UTC 2019-12 N022180-001 7553479 2020-03-08 Drug substance, Drug product 74a2ff9319b5…2019-12-13 00:20 UTC 2019-12 N022180-001 7871597 2020-03-08 Drug substance, Drug product 2011-02-15 74a2ff9319b5…2019-12-13 00:20 UTC 2019-12 N022180-001 8501158 2020-03-08 U-1422 2013-08-06 74a2ff9319b5…2019-12-13 00:20 UTC 2019-12 N022180-001 8591864 2020-03-08 Drug product 2013-12-12 74a2ff9319b5…2019-12-13 00:20 UTC 2019-12 N022180-001 8926947 2020-03-08 Drug substance, Drug product 2015-01-08 74a2ff9319b5…2019-12-13 00:20 UTC 2019-12 N022180-001 6599498 2023-06-30 Drug substance, Drug product 74a2ff9319b5…2022-03-09 01:35 UTC 2022-03 N022180-001 6599498 2023-06-30 Drug substance, Drug product bb7c543d1eb4…2021-12-28 21:50 UTC 2021-12 N022180-001 6599498 2023-06-30 Drug substance, Drug product 782e0a99824c…2021-05-05 16:15 UTC · 3 captures of this ZIP 2021-05 N022180-001 6599498 2023-06-30 Drug substance, Drug product 87673890dc5c…2021-03-12 10:30 UTC 2021-03 N022180-001 6599498 2023-06-30 Drug substance, Drug product 5aa47cf7b7d7…2020-12-22 03:56 UTC 2020-12 N022180-001 7553479 2020-03-08 Drug substance, Drug product 8869cabd3fbd…2020-12-22 03:56 UTC 2020-12 N022180-001 7871597 2020-03-08 Drug substance, Drug product 2011-02-15 8869cabd3fbd…2020-12-22 03:56 UTC 2020-12 N022180-001 8501158 2020-03-08 U-1422 2013-08-06 8869cabd3fbd…2020-12-22 03:56 UTC 2020-12 N022180-001 8591864 2020-03-08 Drug product 2013-12-12 8869cabd3fbd…2020-12-22 03:56 UTC 2020-12 N022180-001 8926947 2020-03-08 Drug substance, Drug product 2015-01-08 8869cabd3fbd…2020-12-22 03:56 UTC 2020-12 N022180-001 6599498 2023-06-30 Drug substance, Drug product 8869cabd3fbd…2020-11-12 02:37 UTC 2020-11 N022180-001 7553479 2020-03-08 Drug substance, Drug product c0c555d07b60…2020-11-12 02:37 UTC 2020-11 N022180-001 7871597 2020-03-08 Drug substance, Drug product 2011-02-15 c0c555d07b60…2020-11-12 02:37 UTC 2020-11 N022180-001 8501158 2020-03-08 U-1422 2013-08-06 c0c555d07b60…2020-11-12 02:37 UTC 2020-11 N022180-001 8591864 2020-03-08 Drug product 2013-12-12 c0c555d07b60…2020-11-12 02:37 UTC 2020-11 N022180-001 8926947 2020-03-08 Drug substance, Drug product 2015-01-08 c0c555d07b60…2020-11-12 02:37 UTC 2020-11 N022180-001 6599498 2023-06-30 Drug substance, Drug product c0c555d07b60…2019-12-14 00:12 UTC 2019-12 N022180-001 7553479 2020-03-08 Drug substance, Drug product 3f01610625f2…2019-12-14 00:12 UTC 2019-12 N022180-001 7871597 2020-03-08 Drug substance, Drug product 2011-02-15 3f01610625f2…2019-12-14 00:12 UTC 2019-12 N022180-001 8501158 2020-03-08 U-1422 2013-08-06 3f01610625f2…2019-12-14 00:12 UTC 2019-12 N022180-001 8591864 2020-03-08 Drug product 2013-12-12 3f01610625f2…2019-12-14 00:12 UTC 2019-12 N022180-001 8926947 2020-03-08 Drug substance, Drug product 2015-01-08 3f01610625f2…2019-12-14 00:12 UTC 2019-12 N022180-001 6599498 2023-06-30 Drug substance, Drug product 3f01610625f2…2019-09-15 20:21 UTC 2019-09 N022180-001 7553479 2020-03-08 Drug substance, Drug product b00525d2431f…2019-09-15 20:21 UTC 2019-09 N022180-001 7871597 2020-03-08 Drug substance, Drug product 2011-02-15 b00525d2431f…2019-09-15 20:21 UTC 2019-09 N022180-001 8501158 2020-03-08 U-1422 2013-08-06 b00525d2431f…2019-09-15 20:21 UTC 2019-09 N022180-001 8591864 2020-03-08 Drug product 2013-12-12 b00525d2431f…2019-09-15 20:21 UTC 2019-09 N022180-001 8926947 2020-03-08 Drug substance, Drug product 2015-01-08 b00525d2431f…2019-09-15 20:21 UTC 2019-09 N022180-001 6599498 2023-06-30 Drug substance, Drug product b00525d2431f…2019-07-19 19:46 UTC 2019-07 N022180-001 7553479 2020-03-08 Drug substance, Drug product ea99ee380514…2019-07-19 19:46 UTC 2019-07 N022180-001 7871597 2020-03-08 Drug substance, Drug product 2011-02-15 ea99ee380514…2019-07-19 19:46 UTC 2019-07 N022180-001 8501158 2020-03-08 U-1422 2013-08-06 ea99ee380514…
Observed Orange Book exclusivity history# openFDA label cross-check# OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
Matched openFDA labels page 1 of 1 · 1 matching rows.
Brand, Generic, Manufacturer table Brand Generic Manufacturer SPL set ID Effective date Available safety fields Join Feraheme FERUMOXYTOL AMAG Pharmaceuticals, Inc 32b0e320-a739-11dc-a704-0002a5d5c51b 2026-05-31 Boxed warning, Warnings, Adverse reactions Exact identifier application applno (NDA): 022180 application number: NDA022180 ndc (product): 59338-775
Reported adverse events (FAERS/openFDA)# Adverse event summaries are temporarily unavailable. Other product information remains available.
NDC Listings For This Application# NDC listings for this application page 1 of 1 · 4 matching rows.
NDC, Name, Nonproprietary name table NDC Name Nonproprietary name Labeler Marketing category Status 59338-775 Feraheme ferumoxytol AMAG Pharmaceuticals, Inc. NDA Current 59338-775 Feraheme ferumoxytol AMAG Pharmaceuticals, Inc. NDA Current 59338-775 Feraheme ferumoxytol AMAG Pharmaceuticals, Inc. NDA Current 59338-775 Feraheme ferumoxytol AMAG Pharmaceuticals, Inc. NDA Current